By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



29 Emmons Drive
Suite C-10
Princeton  New Jersey  08540  U.S.A.
Phone: 609-538-8200 Fax: 609-452-6467


Company News
Soligenix (SNGX) Announces Recent Accomplishments And Third Quarter 2016 Financial Results Highlighted By Revenues Of $3.0 Million 11/11/2016 1:31:45 PM
Soligenix (SNGX) Receives EMA Designation As Small And Medium Enterprise 10/25/2016 6:55:26 AM
Soligenix (SNGX) Announces Publication Of Its Phase 2 Clinical Trial Results Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 10/18/2016 7:33:58 AM
Soligenix (SNGX) To Receive $530,000 In Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program 10/17/2016 10:37:44 AM
Soligenix (SNGX) Announces Poster Presentations From Its Gastrointestinal Acute Radiation Syndrome Program At The 2016 Radiation Research Society Meeting 10/13/2016 7:55:32 AM
Soligenix (SNGX) Announces Poster Presentation Of Its Ricin Vaccine And Dusquetide Orphan Programs At The 2016 NORD Rare Diseases And Orphan Products Breakthrough Summit 10/11/2016 9:46:04 AM
Soligenix (SNGX) Announces Reverse-Split In Preparation For Proposed Up-Listing Of Its Common Stock To The NASDAQ Capital Market 10/7/2016 6:56:51 AM
Soligenix (SNGX) To Present At 2016 Aegis Growth Conference 9/15/2016 10:53:59 AM
Soligenix (SNGX) And SciClone (SCLN) Establish Regional Licensing Agreement For SGX942, A Novel Product Candidate For Oral Mucositis 9/12/2016 6:23:01 AM
Soligenix (SNGX) Announces Issuance Of New Composition Of Matter Patent For Dusquetide Analogs 9/6/2016 8:24:22 AM